Pulmonary Arterial Hypertension (PAH) treatment specialist SoniVie, has been granted Breakthrough Device Designation from the U.S. FDA for the Therapeutic …
continue reading "FDA Breakthrough Device Designation for SoniVie’s TIVUS Pulmonary Arterial Hypertension System"